Q3056485 (Q3056485): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Edited by the beneficiary bot - attach the beneficiary based on the string) |
(Created claim: summary (P836): The aim of the project is to develop personalised NSCLC patient lung cancer on chip (LCoC) and lung to-chip (LOC) as a model system to test the efficacy of drug-filled extracellular vesicles (EV) in lung cancer derived from the patient’s mesenquimal stem cells (MSC) compared to the drug itself. The main result of the project is to show that the EVs from the patient’s MSC are more effective in a personalised environment than simple medications fo...) |
||||||||||||||
| Property / summary | |||||||||||||||
The aim of the project is to develop personalised NSCLC patient lung cancer on chip (LCoC) and lung to-chip (LOC) as a model system to test the efficacy of drug-filled extracellular vesicles (EV) in lung cancer derived from the patient’s mesenquimal stem cells (MSC) compared to the drug itself. The main result of the project is to show that the EVs from the patient’s MSC are more effective in a personalised environment than simple medications for NSCLC therapy. We expect at least 10 patients to develop personalised LCoC, LOC and medication-filled EVs from MSC to test this principle and develop/optimised protocols for personalising LCoC, LOC and recharged therapeutic drugs for EV production within two months of arriving the patient sample. This project consists of several different technologies, therefore it is difficult to evaluate the overall project TLR. For example, lung chip technology is currently in the TLR4 stage, whereas the functionalisation with patient-derived samples is currently in the TLR2 stage. Overall, during this project, we will work towards achieving the TRL5 level of this technology. This project follows the direction of RIS3 “The future growth of sectors where high value-added products and services exist or may emerge” in two areas: “biomedicine, medical technologies, biopharmaceuticals and biotechnologies” and “modern materials, technologies and engineering systems”. This project also corresponds to the economic sector – Professional, scientific and technical services and sub-sector – Research and experimental development in biotechnology – (NACE 72.11) and NACE 86.22, because the results of this project could improve oncologist decision making in the future. This project falls within the category of industrial research and does not involve an economic activity. This is an interdisciplinary study involving biological sciences (1.6), Physics (1.3), Basic Medical (3.1), Material Engineering (2.5), Medical Engineering (2.6) and Nanotechnologies (2.10) according to the OECD classification. This project will be implemented in cooperation between the Latvian Biomedical Research and Study Centre (BMC) and Cellboxlab Ltd., a start-up set up by employees of the Institute of Solid State Physics. The project team will include 2 young scientists (> 25 % of the total workload), as well as students and doctoral candidates (> 25 % of the total workload). The duration of the project is 34 months starting from 1 February 2021. The total eligible funding for the project is EUR 540540,53, including ERDF funding EUR 444810,81.Key words: Extracellular vesicles, lung cancer, targeted drug delivery, organ on chip, microfluidics. (English) | |||||||||||||||
| Property / summary: The aim of the project is to develop personalised NSCLC patient lung cancer on chip (LCoC) and lung to-chip (LOC) as a model system to test the efficacy of drug-filled extracellular vesicles (EV) in lung cancer derived from the patient’s mesenquimal stem cells (MSC) compared to the drug itself. The main result of the project is to show that the EVs from the patient’s MSC are more effective in a personalised environment than simple medications for NSCLC therapy. We expect at least 10 patients to develop personalised LCoC, LOC and medication-filled EVs from MSC to test this principle and develop/optimised protocols for personalising LCoC, LOC and recharged therapeutic drugs for EV production within two months of arriving the patient sample. This project consists of several different technologies, therefore it is difficult to evaluate the overall project TLR. For example, lung chip technology is currently in the TLR4 stage, whereas the functionalisation with patient-derived samples is currently in the TLR2 stage. Overall, during this project, we will work towards achieving the TRL5 level of this technology. This project follows the direction of RIS3 “The future growth of sectors where high value-added products and services exist or may emerge” in two areas: “biomedicine, medical technologies, biopharmaceuticals and biotechnologies” and “modern materials, technologies and engineering systems”. This project also corresponds to the economic sector – Professional, scientific and technical services and sub-sector – Research and experimental development in biotechnology – (NACE 72.11) and NACE 86.22, because the results of this project could improve oncologist decision making in the future. This project falls within the category of industrial research and does not involve an economic activity. This is an interdisciplinary study involving biological sciences (1.6), Physics (1.3), Basic Medical (3.1), Material Engineering (2.5), Medical Engineering (2.6) and Nanotechnologies (2.10) according to the OECD classification. This project will be implemented in cooperation between the Latvian Biomedical Research and Study Centre (BMC) and Cellboxlab Ltd., a start-up set up by employees of the Institute of Solid State Physics. The project team will include 2 young scientists (> 25 % of the total workload), as well as students and doctoral candidates (> 25 % of the total workload). The duration of the project is 34 months starting from 1 February 2021. The total eligible funding for the project is EUR 540540,53, including ERDF funding EUR 444810,81.Key words: Extracellular vesicles, lung cancer, targeted drug delivery, organ on chip, microfluidics. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: The aim of the project is to develop personalised NSCLC patient lung cancer on chip (LCoC) and lung to-chip (LOC) as a model system to test the efficacy of drug-filled extracellular vesicles (EV) in lung cancer derived from the patient’s mesenquimal stem cells (MSC) compared to the drug itself. The main result of the project is to show that the EVs from the patient’s MSC are more effective in a personalised environment than simple medications for NSCLC therapy. We expect at least 10 patients to develop personalised LCoC, LOC and medication-filled EVs from MSC to test this principle and develop/optimised protocols for personalising LCoC, LOC and recharged therapeutic drugs for EV production within two months of arriving the patient sample. This project consists of several different technologies, therefore it is difficult to evaluate the overall project TLR. For example, lung chip technology is currently in the TLR4 stage, whereas the functionalisation with patient-derived samples is currently in the TLR2 stage. Overall, during this project, we will work towards achieving the TRL5 level of this technology. This project follows the direction of RIS3 “The future growth of sectors where high value-added products and services exist or may emerge” in two areas: “biomedicine, medical technologies, biopharmaceuticals and biotechnologies” and “modern materials, technologies and engineering systems”. This project also corresponds to the economic sector – Professional, scientific and technical services and sub-sector – Research and experimental development in biotechnology – (NACE 72.11) and NACE 86.22, because the results of this project could improve oncologist decision making in the future. This project falls within the category of industrial research and does not involve an economic activity. This is an interdisciplinary study involving biological sciences (1.6), Physics (1.3), Basic Medical (3.1), Material Engineering (2.5), Medical Engineering (2.6) and Nanotechnologies (2.10) according to the OECD classification. This project will be implemented in cooperation between the Latvian Biomedical Research and Study Centre (BMC) and Cellboxlab Ltd., a start-up set up by employees of the Institute of Solid State Physics. The project team will include 2 young scientists (> 25 % of the total workload), as well as students and doctoral candidates (> 25 % of the total workload). The duration of the project is 34 months starting from 1 February 2021. The total eligible funding for the project is EUR 540540,53, including ERDF funding EUR 444810,81.Key words: Extracellular vesicles, lung cancer, targeted drug delivery, organ on chip, microfluidics. (English) / qualifier | |||||||||||||||
point in time: 15 July 2021
| |||||||||||||||
Revision as of 12:35, 15 July 2021
Project Q3056485 in Latvia
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q3056485 in Latvia |
Statements
444,810.8 Euro
0 references
540,540.53 Euro
0 references
1 February 2021
0 references
30 November 2023
0 references
Atvasināta publiska persona "Latvijas Biomedicīnas pētījumu un studiju centrs"
0 references
56°54'57.24"N, 24°9'56.95"E
0 references
56°58'59.81"N, 24°1'53.44"E
0 references
Projekta mērķis ir izstrādāt personalizētu NSCLC pacienta plaušu vēzi uz čipa (LCoC) un plaušu uz čipa (LoC) kā modeļa sistēmas, lai pārbaudītu ar zāļvielām pildītas ārpusšūnu vezikulu (EV) efektivitāti plauša vēža terapijā, kas iegūtas no pacienta mezenhimalām cilmes šūnām (MSC) salīdzinājumā ar zālēm pašām par sevi. Galvenais projekta rezultāts ir parādīt, ka ar zāļvielām pildītās EVs, kas iegūti no pacienta MSC, ir personalizētā vidē efektīvāki nekā vienkārši medikamenti NSCLC terapijai. Mēs sagaidām, ka vismaz 10 pacientiem tiks izstrādāts personalizēts LCoC, LoC un ar medikamentiem pildītas EVs no MSC, lai pārbaudītu šo principu un izstrādātu / optimizētu protokolus LCoC, LoC personalizēšanai un terapeitisko zāļu pielādētu EV ražošanai divu mēnešu laikā no brīža, kad ierodas pacienta paraugs. Šis projekts sastāv no vairākām, dažādām tehnoloģijām, tāpēc kopējo projekta TLR ir sarežģīti novērtēt. Piemēram, plaušu čipu tehnoloģija pašlaik atrodas TLR4 stadijā, turpretī funkcionalizācija ar pacientu atvasinātiem paraugiem šobrīd ir TLR2 stadijā. Kopumā šī projekta laikā mēs strādāsim pie šīs tehnoloģijas TRL5 līmeņa sasniegšanas. Šis projekts atbilst RIS3 virzienam “To nozaru turpmākā izaugsme, kurās pastāv vai var parādīties produkti un pakalpojumi ar augstu pievienoto vērtību” divās jomās: “biomedicīna, medicīnas tehnoloģijas, biofarmācija un biotehnoloģijas” un “moderni materiāli, tehnoloģijas un inženierijas sistēmas ”. Kā arī šis projekts atbilst tautsaimniecības nozarei - Profesionālie, zinātniskie un tehniskie pakalpojumi un apakšnozarei - Pētījumu un eksperimentālo izstrāžu veikšana biotehnoloģijā –(NACE 72.11) un NACE 86.22, jo šī projekta rezultāti nākotnē varētu uzlabot onkologa lēmumu pieņemšanu terapijā. Šis projekts atbilst rūpniecisko pētījumu kategorijai un nav saistīts ar saimniecisko darbību. Šis ir starpnozaru pētījums, kurā iesaistītas bioloģiskās zinātnes (1.6.), Fizikas zinātnes (1.3.), Pamata Medicīna (3.1.), Materiālu inženierija (2.5.), Medicīnas inženierija (2.6.) un nanotehnoloģijas (2.10.) saskaņā ar ESAO klasifikāciju. Šis projekts tiks īstenots sadarbībā starp Latvijas Biomedicīnas pētījumu un studiju centru (BMC) un SIA Cellboxlab, Cietvielu fizikas institūta darbinieku izveidoto jaunuzņēmumu. Projekta komandā būs 2 jauni zinātnieki (> 25% no kopējās darba slodzes), kā arī studenti un doktora grāda pretendenti (> 25% no kopējās darba slodzes). Projekta ilgums ir 34 mēneši, sākot no 2021. gada 1. februāra. Projekta kopējais attiecināmais finansējums ir 540 540,53 EUR, ieskaitot ERAF finansējumu 444 810,81 EUR.Atslēgas vārdi: ārpusšūnu vezikulas, plaušu vēzis, mērķtiecīga zāļu piegāde, orgāns uz čipa, mikrofluidika. (Latvian)
0 references
The aim of the project is to develop personalised NSCLC patient lung cancer on chip (LCoC) and lung to-chip (LOC) as a model system to test the efficacy of drug-filled extracellular vesicles (EV) in lung cancer derived from the patient’s mesenquimal stem cells (MSC) compared to the drug itself. The main result of the project is to show that the EVs from the patient’s MSC are more effective in a personalised environment than simple medications for NSCLC therapy. We expect at least 10 patients to develop personalised LCoC, LOC and medication-filled EVs from MSC to test this principle and develop/optimised protocols for personalising LCoC, LOC and recharged therapeutic drugs for EV production within two months of arriving the patient sample. This project consists of several different technologies, therefore it is difficult to evaluate the overall project TLR. For example, lung chip technology is currently in the TLR4 stage, whereas the functionalisation with patient-derived samples is currently in the TLR2 stage. Overall, during this project, we will work towards achieving the TRL5 level of this technology. This project follows the direction of RIS3 “The future growth of sectors where high value-added products and services exist or may emerge” in two areas: “biomedicine, medical technologies, biopharmaceuticals and biotechnologies” and “modern materials, technologies and engineering systems”. This project also corresponds to the economic sector – Professional, scientific and technical services and sub-sector – Research and experimental development in biotechnology – (NACE 72.11) and NACE 86.22, because the results of this project could improve oncologist decision making in the future. This project falls within the category of industrial research and does not involve an economic activity. This is an interdisciplinary study involving biological sciences (1.6), Physics (1.3), Basic Medical (3.1), Material Engineering (2.5), Medical Engineering (2.6) and Nanotechnologies (2.10) according to the OECD classification. This project will be implemented in cooperation between the Latvian Biomedical Research and Study Centre (BMC) and Cellboxlab Ltd., a start-up set up by employees of the Institute of Solid State Physics. The project team will include 2 young scientists (> 25 % of the total workload), as well as students and doctoral candidates (> 25 % of the total workload). The duration of the project is 34 months starting from 1 February 2021. The total eligible funding for the project is EUR 540540,53, including ERDF funding EUR 444810,81.Key words: Extracellular vesicles, lung cancer, targeted drug delivery, organ on chip, microfluidics. (English)
15 July 2021
0 references
Rātsupītes iela 1 k-1, Rīga, LV-1067
0 references
Ķengaraga iela 8, Rīga, LV-1063
0 references
Identifiers
1.1.1.1/20/A/124
0 references